HealthCanada to review Botox safety

The FDA hasn't hopped on Public Citizen's demand for a warning of safety problems with the commonly used wrinkle-fighter Botox. Health Canada, however, says it's reviewing safety information on the drug, approved in that country for cosmetic purposes and for treatment of muscle tics and stiffness.

The Canadian drug regulator says it started checking into safety data after some European studies indicated that the drug--botulinum toxin--might spread from the injection site and cause adverse reactions. "[A]fter a thorough review, Health Canada will take action, if necessary," the agency said.

Public Citizen wrote the FDA last week, asking for warnings about Botox and its sister drug Myobloc (made by Allergan and Solstice Neurosciences, respectively). The petition included information on hundreds of mild and severe reactions to the drugs, reported in Europe and the U.S.

- read the report from The Canadian Press
- check out Public Citizen's petition to the FDA

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.